Prix bas
CHF136.80
Habituellement expédié sous 2 à 4 semaines.
Auteur
Joan Cabestany holds a Telecommunications Engineer degree (1976) from the Universitat Politècnica de Catalunya (UPC) in Barcelona, Spain. He got his PhD (1982) from the same University, where he is working as a Full-time Professor in the Department of Electronic Engineering. He was the responsible for the AHA (Advanced Hardware Architectures) research group at UPC, with expertise on reconfigurable hardware, electronic system design, advanced hardware architectures, microelectronics, and VLSI design. One of his main topics of interest has been the practical application of Artificial Intelligence to the functional improvement of electronic systems. More recently, he has been an active member of the ISSET (Integrated Smart Sensors and Health Technologies) research group. He was founder of the CETpD Research Center at UPC in 2005, covering activities focused on technological developments applied to the improvement and help of people with chronic diseases, like Parkinson's Disease and different conditions related to aging. Professor Cabestany has been responsible for several EU-funded projects. Among them, the REMPARK project on PD management and the FATE project for the accurate detection of falls in aging people are the two projects. He is also the co-author for more than 100 research papers and communications to Conferences. Professor Cabestany is a co-founder of the Sense4Care SL company (www.sense4care.com). The SME company is a spin-off of the UPC, commercializing relevant innovative research results. Among them, the STAT-ONTM Holter is, currently, the most relevant.
Angels Bayés MD is a Doctor in Medicine, and Neurology specialist. Her career and research activity has been focused on the study and treatment of movement disorders like Parkinson's disease (PD), Tourette syndrome, and on dementias, like Alzheimer's disease. She has been the director of the Unit for Movement Disorders and Parkinson of TEKNON Medical Center in Barcelona (Spain) for the last 20 years. Her main research areas are related to the implementation of holistic treatment to improve the quality of life of patients suffering from movement disorders. For the last 13 years, she has been cooperating with an engineering team at Universitat Politècnica de Catalunya, in Barcelona, for the development and implementation of technological solutions for the support and management of PD. She has participated in 42 research projects, with special mention for the EU funded EDUPARK and REMPARK. She has authored 71 publications, including 6 books, many conferences, communications, and teaching courses.
Résumé
A new information and communication technology (ICT) has been deployed in the battle against Parkinson's disease, a neurodegenerative disorder that is both progressive and disabling with significant impact on quality of life. This book explains the experience following from the achieved results in the REMPARK project on Parkinson's disease management up to the launch of a new medical product to the European market, STAT-ON™.
The new medical device, STAT-ON™ is a real Holter for the motor symptoms associated to PD. It provides objective information about the severity and distribution of PD motor symptoms and their fluctuations in daily life, allowing for an unbiased and correct monitoring of the patient. This real-time remote monitoring solution gives additional information to neurologists, opening up new possibilities for more effective treatment, more accurate control in clinical trials, and for early detection of motor complications.
The number of PD patients is continuously rising, adding complexity, especially in the management at the level of public health. It is an incurable disease, with a symptomatic treatment that tries to alleviate the associated symptoms through a correct adjustment of the medication. For this reason, it is also very important to be aware of changes in the manifestation of the symptoms, which may indicate the need for an adjustment or even a change in the therapy strategy.
The intensive complementary use of STAT-ON™ by neurologists, health professionals and researchers, will increase the independence and quality of life of patients, improving their disease management, and contributing to a deeper understanding of the nature of the disease.
Contenu